ADA and chronic obstructive pulmonary disease: Treatment of ADORA2B antagonist in this ADA-deficient COPD mouse model led to the attenuation of PH through a regulation of hyaluranon and hyaluranon synthase-2, suggesting that adenosine signaling influences lung extracellular matrix composition which leads to remodeling [128].